MedPath

Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

Terminated
Conditions
Turner's Syndrome
Growth Hormone Deficiency
Interventions
Registration Number
NCT02018172
Lead Sponsor
Ferring Pharmaceuticals
Brief Summary

The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
3
Inclusion Criteria
  • Patient with growth hormone deficiency,

    1. Diagnosis of growth hormone deficiency proven by appropriate exploration
    2. Size ≤ -2 Standard Deviation (SD) according to the French references
    3. Growth velocity in the previous year inferior to the normal for age (-1SD) or < 4cm/year
  • Growth deficiency due to Turner's syndrome

    1. Turner's syndrome confirmed by a karyotype
    2. Patient's size ≤ -2 SD according to the French references
    3. Bone age < 12 years
  • Patient who require a minimum of 18 months of treatment.

Exclusion Criteria
  • There are no exclusion criteria except the contraindication for Zomacton® 10 mg

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Zomacton® treatment with Zomajet® Vision X devicesomatropin-
Primary Outcome Measures
NameTimeMethod
Rate of overall treatment adherenceUp to 18 months

Ratio between actual duration of administration and total duration recommended by physician

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hôpital des Enfants, CHU de Toulouse

🇫🇷

Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath